TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29447772
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 75-160 mg daily
Study: 25941174
Drug: Daily ozone
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily ozone levels on the day before a PCV
Study: 25941174
Drug: Daily PM2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily PM2.5 levels on the day before a PCV (December to March)
Study: 15504288
Drug: Sequence administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequence administration of lamivudine and interferon alpha 1b
Study: 15504288
Drug: No anti-virus
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anti-virus therapy (control group)
Study: 9307197
Drug: Preradiation chemotherapy
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preradiation chemotherapy consisting of methotrexate 120 mg/m2, cisplatin 100 mg/m2, 5-fluorouracil 1000 mg/m2 for five days, leucovorin 25 mg/m2 every six hours for 6 doses, followed by radiation therapy and adjuvant IFN-beta (10^5 U/kg) 3 times a week for 6 months.
Study: 9307197
Drug: Radiotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy with a cumulative dose of 59.4 Gy to primary sites and 45 Gy to the neck area.
Study: 8354807
Drug: Central administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Central administration of adenosine (3 mg)
Study: 8354807
Drug: Central administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Central administration of adenosine (6 mg)
Study: 8354807
Drug: Central administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Central administration of adenosine (9 mg)
Study: 8354807
Drug: Peripheral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peripheral administration of adenosine (3 mg)
Study: 8354807
Drug: Peripheral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peripheral administration of adenosine (6 mg)
Study: 8354807
Drug: Peripheral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peripheral administration of adenosine (9 mg)
Study: 8354807
Drug: Peripheral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peripheral administration of adenosine (12 mg)
Study: 24101860
Drug: Aescin 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aescin 10% cream applied immediately after the procedure, in the evening, and the morning after
Study: 21843889
Drug: 21 active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 active pills + 7 placebo pills (21/7 COC)
Study: 21843889
Drug: 24 active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 active pills + 4 placebo pills (24/4 COC)
Study: 17885297
Drug: High maternal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High maternal CRP concentration (> 10 mg/l)
Study: 15153210
Drug: Ketamine 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 6 mg.kg(‐1) per oral
Study: 9564606
Drug: Selegiline (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline (10, 30, or 60 mg/day for three or more weeks)
Study: 9564606
Drug: Pargyline (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pargyline (90 mg/day for three or more weeks)
Study: 9564606
Drug: Clorgyline (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clorgyline (30 mg/day for three or more weeks)
Study: 9564606
Drug: Selegiline (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline (higher doses than 10 mg/day)
Study: 9564606
Drug: Selegiline and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline and Pargyline (highest doses)
Study: 31362061
Drug: OLE treatment
Normalized name: limonen-10-ol, (+)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: OLE treatment
Study: 23980349
Drug: Xiaozhi Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiaozhi Capsule (XZC)
Study: 23980349
Drug: Xuezhikang Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuezhikang Capsule (XZKC)
Study: 17853008
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg/daily for 4 weeks
Study: 17853008
Drug: Diclofenac 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 100 mg on demand for 4 weeks plus levofloxacin 250 mg daily for the first week
Study: 16597040
Drug: Naftopidil (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftopidil (25 mg once a day for 4 weeks)
Study: 11181464
Drug: Ramipril 10
Normalized name: ramipril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 10 mg/d
Study: 11001109
Drug: 7-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-valent pneumococcal conjugate vaccine (7VPnC) administered as a separate injection
Study: 11001109
Drug: 7-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-valent pneumococcal conjugate vaccine (7VPnC) combined with Haemophilus influenzae type b vaccine (HbOC)
Study: 11001109
Drug: Routine vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine vaccines only (control group)
Study: 6705277
Drug: 3 injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 injections of 1 ml (Group I)
Study: 6705277
Drug: 3 injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 injections of 2 ml (Group II)
Study: 6705277
Drug: 4 injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 injections of 1 ml (Group III)
Study: 30126781
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure therapy (Prevena)
Study: 9531078
Drug: Primary chemotherapy
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary chemotherapy followed by simultaneous resection of primary and metastatic lesions (when feasible) and further chemotherapy
Study: 9531078
Drug: Simultaneous surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous surgical treatment of primary and metastatic tumor
Study: 9531078
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment including chemotherapy and surgery
Study: 1092576
Drug: Attenuated influenza
Normalized name: Live attenuated influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attenuated influenza virus vaccine (ANN strain)
Study: 25008799
Drug: Naso-gastric infusion
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naso-gastric infusion of 500mL/0kJ water (Stomach distention)
Study: 25008799
Drug: Naso-gastric infusion
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naso-gastric infusion of 500mL/1770kJ chocolate milk (Stomach distention with caloric content)
Study: 25008799
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 500mL/1770kJ chocolate milk (Stomach distention with caloric content and oral exposure)
Study: 15705690
Drug: Rectal artemether
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal artemether
Study: 10368486
Drug: Sequential use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential use of instruments (vacuum first, then forceps, or vice versa)
Study: 8888321
Drug: 2.5-mg silver
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5-mg silver acetate lozenge
Study: 2058340
Drug: Latamoxef 2
Normalized name: latamoxef
DrugBank: Latamoxef (DB04570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Latamoxef 2 g single-dose prophylaxis
Study: 20595283
Drug: Injection therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection therapies
Study: 20595283
Drug: Drug-based intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug-based intervention
Study: 15923248
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with salmeterol and fluticasone propionate (SFC)
Study: 11864664
Drug: Soy isoflavone
Normalized name: soy isoflavone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavone 100 mg daily for 4 months
Study: 7566021
Drug: Margarine containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Margarine containing sitostanol ester (1.8 or 2.6 g of sitostanol per day)
Study: 2090399
Drug: Bendazac lysine
Normalized name: bendazac lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendazac lysine (anti-cataract drug)
Study: 28024935
Drug: Nitrate (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate (140 mL·day−1 NO3−‐rich beetroot juice, 8.4 mmol NO3−·day−1)
Study: 28024935
Drug: Nitrate +
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate + Iodide (140 mL·day−1 NO3−‐rich beetroot juice and 450 μg potassium iodide·day−1)
Study: 19363857
Drug: 0.1% tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% tretinoin gel
Study: 16709386
Drug: Levosimendan (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (loading dose of 12 microg/kg followed by 24-hour infusion of 0.2 microg/kg per min)
Study: 16709386
Drug: Dobutamine (24-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine (24-hour infusion of 7.5 microg/kg per min)
Study: 11776446
Drug: 4.0 J/cm2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 J/cm2 treatment group
Study: 11776446
Drug: 1.7 J/cm2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.7 J/cm2 treatment group
Study: 9621294
Drug: OTZ (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTZ (0.5 g three times a day orally with meals)
Study: 31560066
Drug: Apalutamide (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apalutamide (240 mg daily)
Study: 29198449
Drug: Flibanserin 100
Normalized name: flibanserin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flibanserin 100 mg once daily for 14 days
Study: 29198449
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive alone (reference)
Study: 15266201
Drug: Innovative research
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Innovative research designs and psychosocial treatments
Study: 9357184
Drug: Metronidazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (400 mg tid for 10 days, followed by placebo for 50 days)
Study: 9357184
Drug: Isapghul (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isapghul (10 g bid for 60 days)
Study: 9357184
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 capsule bid for 60 days)
Study: 8479248
Drug: Cumulative fraction
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative fraction absorbed‐time profile method of paracetamol
Study: 8479248
Drug: Proportional area
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proportional area under the curve method of paracetamol
Study: 3083092
Drug: Intravenous 1‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 1‐mg dose of leuprolide
Study: 3083092
Drug: Subcutaneous 1‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous 1‐mg dose of leuprolide
Study: 3083092
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of intravenous and subcutaneous administration
Study: 23316876
Drug: Oral (PO)
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral (PO) therapy
Study: 23316876
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) therapy
Study: 23316876
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) therapy
Study: 18378313
Drug: Medication (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (n = 596)
Study: 18378313
Drug: Topical prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical prostaglandin analogues (PGAs)
Study: 9540780
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulant (INR 2.5)
Study: 9540780
Drug: Subcutaneous calcium
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous calcium heparin 0.2 ml bid (8.00 and 20.00)
Study: 9540780
Drug: Subcutaneous calcium
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous calcium heparin (0.5 ml at 20.00)
Study: 8112905
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ST-depression and low maximal work load
Study: 14658256
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy without indomethacin
Study: 8923361
Drug: Sulfasalazine (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfasalazine (target dosage, 40 mg/kg/day)
Study: 8923361
Drug: Auranofin (6‐9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auranofin (6‐9 mg/day)
Study: 1399378
Drug: Omeprazole, 40
Normalized name: Omeprazole, 40 mg oral delayed release capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole, 40 mg o.m., for 10 days
Study: 3888030
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg sodium fluoride daily
Study: 25523634
Drug: Weekly low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weekly low-dose methotrexate (MTX) as an add-on therapy
Study: 17454467
Drug: Lidocaine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (10 ml 2% lidocaine) injected down the drain before removal
Study: 14997327
Drug: Age-related increase
Normalized name: casein, Lactococcus lactis cultured, aged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age-related increase in LEP(u/l)
Study: 11361048
Drug: CS-866 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-866 (oral administration)
Study: 11361048
Drug: RNH-6270 (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: RNH-6270 (intravenous administration)
Study: 11361048
Drug: CS-866 (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-866 (up to 160 mg/day)
Study: 7803318
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy (16 sessions over a six-month period)
Study: 30916626
Drug: Penile traction
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penile traction therapy with RestoreX device for 30 to 90 minutes per day
Study: 22237835
Drug: Gemcitabine 1
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1 g/m2 weekly on days 1, 8, and 15 (arm A)
Study: 22237835
Drug: PEFG regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEFG regimen (cisplatin and epirubicin 40 mg/m2, day 1; gemcitabine 600 mg/m2, days 1, 8; 5-fluorouracil 200 mg/m2 daily, days 1-28) (arm B)
Study: 17362049
Drug: Various immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various immunotherapy approaches (including dendritic cell vaccination, whole cell vaccines, and recombinant viral vectors)
Study: 17362049
Drug: Chemotherapy (taxane-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (taxane- and platinum-compound-based)
Study: 15894038
Drug: 2.5% glycyrrhetinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% glycyrrhetinic acid cream (n=9)
Study: 15894038
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream (n=9)
Study: 12080401
Drug: Prototype beta‐glucan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prototype beta‐glucan cereal (8.1 g% beta‐glucan)
Study: 12080401
Drug: Beta‐glucan bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta‐glucan bar (6.5 g% beta‐glucan)
Study: 12080401
Drug: Commercial oat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial oat bran breakfast cereal (4.4 g% beta‐glucan)
Study: 2019667
Drug: Etoposide (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide (600 mg/m2) + Cisplatin (100 mg/m2) administered intraperitoneally
Study: 7078417
Drug: ZnSO4 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZnSO4 (100 mg/day Zn++)
Study: 30821349
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at 50-150 μg/kg/min (Group P)
Study: 30821349
Drug: Dexmedetomidine bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine bolus of 1 μg/kg followed by infusion at 0.5-1.0 μg/kg/hr (Group D)
Study: 28673215
Drug: Ketamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusion (0.5 mg/kg pre‐incision, 0.25 mg/kg/hour intraoperatively, 0.1 mg/kg/hour for 24 hours)
Study: 28673215
Drug: Ketamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusion and Placebo
Study: 25771141
Drug: 2% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% chlorhexidine gel (GII)
Study: 25771141
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (GIII, control group)
Study: 21584666
Drug: Epirubicin 110
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 110 mg/m(2) + Paclitaxel 200 mg/m(2) every 21 days (dose-escalated)
Study: 21584666
Drug: Epirubicin 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 75 mg/m(2) + Paclitaxel 175 mg/m(2) every 10 days (dose-dense)
Study: 26976659
Drug: Yoga in
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yoga in combination with standard treatment
Study: 21166600
Drug: valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: valsartan 160 mg once daily in the morning
Study: 21166600
Drug: valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: valsartan 160 mg once daily in the evening
Study: 19877092
Drug: Tai Chi
Normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tai Chi (60 minutes, 10 modified forms from classic Yang style, twice weekly for 12 weeks)
Study: 11296615
Drug: Amifostine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifostine (500 mg) administered on days carboplatin was given
Study: 9290304
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment for lymphoedema
Study: 3103174
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml 0.42% carbonated bupivacaine
Study: 3103174
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml 0.5% bupivacaine hydrochloride
Study: 22438072
Drug: Densulin® N
Approvals — FDA: no, EMA: no, PMDA: no
Description: Densulin® N (NPH) plus Densulin® R (regular), 100 UI/ml
Study: 22438072
Drug: InsulatardHM® (NPH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: InsulatardHM® (NPH) plus ActrapidHM®, 100 UI/ml
Study: 12208797
Drug: 50 microg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 microg/d transdermal E2
Study: 12208797
Drug: 0.625 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg/d oral CEE
Study: 12080685
Drug: Ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 8 mg in 10 ml solution
Study: 12080685
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% NS 10 ml)
Study: 1773686
Drug: Patient activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient activation intervention (45-min intervention + 1-h self-administered booster)
Study: 30488367
Drug: Combined immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined immunosuppressive treatment (CIST) including intravenous cyclophosphamide, mycophenolate mofetil, azathioprine, leflunomide, hydroxychloroquine, and glucocorticoids.
Study: 30488367
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide (CYC) alone with glucocorticoids.
Study: 24842445
Drug: Dexamethasone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (10 mg or 30 mg total dose)
Study: 20032533
Drug: Ritonavir-boosted protease
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir-boosted protease inhibitors with rifampicin
Study: 20032533
Drug: Adjusted dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted dose protease inhibitors with rifampicin
Study: 11794812
Drug: New design
Approvals — FDA: no, EMA: no, PMDA: no
Description: New design of tablets with a hydrophilic matrix containing 300 mg of diltiazem
Study: 11794812
Drug: Capsules containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules containing prolonged liberation microgranules of 300 mg of diltiazem (reference formulation)
Study: 10189261
Drug: Carbatrol (CBTL)
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbatrol (CBTL) 400 mg b.i.d. for 5 days
Study: 10189261
Drug: Tegretol-XR (TXR)
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tegretol-XR (TXR) 400 mg b.i.d. for 5 days
Study: 24349363
Drug: S-1-based chemotherapy
Normalized name: menthol 1 MG [Luden's]
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1-based chemotherapy